Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has acquired three anti-inflammatory brands from Mumbai-based Aksigen Hospital Care. The company has acquired Disperzyme, Disperzyme-CD and Phlogam as part of the deal.

All the brands are approved by the Drugs Controller General of India (DCGI) for post-operative inflammation in patients undergoing minor surgery and dental procedures. Disperzyme and Phlogam are the first enzyme-bioflavonoid combinations of Trypsin, Bromelain and Rutoside to complete a clinical study in India and get DCGI approval.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.